New study checks cost and effects of two immunotherapies for bladder cancer
NCT ID NCT07207928
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study looked at how well two immunotherapy drugs, Avelumab and Pembrolizumab, work for people with advanced bladder cancer that didn't get worse after initial chemotherapy. Researchers tracked 35 patients to see how long the drugs controlled the cancer, what side effects occurred, and the overall costs. The goal was to understand real-world benefits and risks of these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria Integrata di Verona
Verona, Verona, 37134, Italy
Conditions
Explore the condition pages connected to this study.